Azora Therapeutics, Inc. (DE) (AZR): who owns it and who trades it
As of Nov 9, 2026, AZR insiders reported 5 purchases worth $106K in the last 12 months. The largest buyer was Coastlands Capital LP (10% owner), with $106K.
Latest filing Nov 9, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, AZR insiders reported $106K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Coastlands Capital LP | 10% owner | Purchase | 1,233 | $2.75 | $3.4K | Form 4 |
| Jul 14, 2026 | Coastlands Capital LP | 10% owner | Purchase | 2,000 | $2.65 | $5.3K | Form 4 |
| Jul 10, 2026 | Coastlands Capital LP | 10% owner | Purchase | 1,700 | $2.70 | $4.6K | Form 4 |
| Jul 9, 2026 | Coastlands Capital LP | 10% owner | Purchase | 10,053 | $2.79 | $28K | Form 4 |
| Jun 29, 2026 | Coastlands Capital LP | 10% owner | Purchase | 25,000 | $2.60 | $65K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Coastlands Capital LP | 10% owner | $106K | – | Jul 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AZR short interest
Moderate short interest. 8.3% of AZR shares are sold short: about 1 share in 12.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 217,174 AZR shares were sold short, 8.3% of the shares outstanding, up 20.9% from the report before. At the average daily volume of 52,562 shares, buying them all back would take about 4.1 trading days (days to cover).
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 217,174 | 8.27% | +21% | 52,562 | 4.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Azora Therapeutics, Inc. (DE) company events
Azora Therapeutics, Inc. (DE) filed 19 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.
- Nov 9, 2026LeadershipEach of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appointed to the Board of Directors of Azora Therapeutics, Inc. (formerly known as Adial Pharmaceuticals, Inc.). Filing
- Oct 28, 2026LeadershipAppointment of Chief Executive Officer The Board of Directors of Azora Therapeutics, Inc., formerly known as Adial Pharmaceuticals, Inc., appointed Matthew Davidson, Ph.D. as President and Chief Executive Officer of the Company, on October 28, 2026. Filing
- Oct 16, 2026AnnouncementAs previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. with the Securities and Exchange Commission on September 18, 2026, on September 17, 2026, the Company convened its 2026 Annual Meeting of Stockholders. Filing
- Oct 2, 2026AnnouncementAs previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. with the Securities and Exchange Commission on September 18, 2026, on September 17, 2026, the Company convened its 2026 Annual Meeting of Stockholders. Filing
- Sep 18, 2026LeadershipAdial Pharmaceuticals, Inc. convened its 2026 Annual Meeting of Stockholders. Filing
- Sep 16, 2026AgreementAfter the closing of the PIPE and the Note Exchange, it was determined that, for accounting purposes, the Penalty Provision in the Purchase Agreement and Exchange Agreements caused the entire value of the Milestone Warrants that the PIPE Investors and Former Azora Noteholders have a right to… Filing
- Aug 25, 2026SharesSold new shares outside a public offering. Filing
- Aug 21, 2026ListingAdial Pharmaceuticals, Inc. received a letter from The Nasdaq Stock Market notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no longer satisfies the minimum stockholders’ equity… Filing
- Aug 17, 2026ResultsReleased financial results. Filing
- Aug 13, 2026LeadershipAdial Pharmaceuticals, Inc. anticipates that the employment of its current President and Chief Executive Officer, Cary Claiborne, will be terminated effective promptly after the Company’s 2026 Annual Meeting of Stockholders if certain of the proposals being presented to stockholders are approved… Filing
- Jun 11, 2026LeadershipBelow, is participating in the Financing and agreed to purchase Initial Closing Pre-Funded Warrants to purchase 36,378 shares of Common Stock for an aggregate purchase price of $100,000 at the Initial Closing. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 9, 2026LeadershipThe Compensation Committee of the Board of Directors of Adial Pharmaceuticals, Inc., a Delaware corporation, approved the grant of restricted stock awards to the Company’s named executive officers, as follows: ● 37,985 RSAs to Cary Claiborne, the Company’s Chief Executive Officer and a Director… Filing
- Mar 6, 2026ResultsReleased financial results. Filing
- Mar 3, 2026AnnouncementAdial Pharmaceuticals, Inc. called to order its Special Meeting of Stockholders. Filing
- Feb 24, 2026AnnouncementAdial Pharmaceuticals, Inc. received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the Staff has determined that for the last 10 consecutive business days, from February 6, 2026 through February 20, 2026, the closing bid price of the… Filing
- Feb 4, 2026AnnouncementThe primary purpose of the 1-for-25 Reverse Stock Split is to raise the per-share trading price of the Common Stock to allow for its continued listing on the Nasdaq Capital Market, among other benefits, including making the bid price more attractive to a broader group of institutional and retail… Filing
- Jan 6, 2026LeadershipJames W. Newman, Jr., a member of the Board of Directors of Adial Pharmaceuticals, Inc., notified the Company of his decision to resign, effective immediately, from his position as a member of the Board. Filing
- Dec 1, 2025AgreementAdial Pharmaceuticals, Inc. entered into a warrant inducement agreement with a certain holder named therein of Series C-1 Common Stock Purchase Warrants to purchase up to 4,025,000 shares of the Company’s common stock, par value $0.001 per share, originally issued on May 5, 2025 and Series E Common… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named AZR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 3, 2026 | Coastlands Capital LP | 13G/A | 5.0% |
| Nov 3, 2026 | Coastlands Capital LP | 13G/A | 5.0% |
Questions about Azora Therapeutics, Inc. (DE) (AZR) stock
Are AZR insiders buying or selling?
In the last 12 months, AZR insiders reported 5 open-market purchases worth $106K and no sales. The latest trade was on Jul 16, 2026. See every trade.
What is the short interest in AZR?
As of Oct 30, 2026, 217,174 AZR shares were sold short, 8.3% of the shares outstanding, up 20.9% from the report before. At the average daily volume of 52,562 shares, buying them all back would take about 4.1 trading days (days to cover). See the history.
Executive pay
Azora Therapeutics, Inc. (DE)'s chief executive was paid a total of $891K for the year ended Dec 31, 2025, down 9% from $976K the year before. In the last 12 months, Azora Therapeutics, Inc. (DE)'s executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.